We offer a weekly Journal Club focusing on "Cancer Immunotherapy" which takes place on Mondays at 9.00 a.m. with more than 30 participants from different departments and research programs of the DKFZ and NCT. The seminar participants are Master and PhD students, postdocs and group leaders. Our aim is to critically review the newest literature in the field of cancer immunotherapy.


Each participant presents a paper approximately every 8 months in a 30 to 40 min Powerpoint presentation. The publication is then discussed by all attendies. Since mid of 2015 more than 160 papers have been presented..

Due to the Corona virus situation, the journal club is presently completely virtually given as video conference with a shared presentation. Discussion is possible. 

If you are interested to join, please contact S. Eichmüller, who is organizing this seminar. Participation can be confirmed for the PhD program.

list of papers presented so far can be found here (pdf-file; updated 2021-05-03).


Most recent papers presented (update 2021-05-03)

  • Mills et al., 2019. Cell Reports. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment
  • Li et al., 2020. Can Imm Res. Tumor cell–intrinsic USP22 suppresses antitumor immunity in pancreatic cancer
  • van den Eynden et al., 2019. Nature Genetics. Lack of detectable neoantigen depletion signals in the untreated cancer genome
  • Gauthier et al., 2019. Cell. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
  • Crowther et al., 2020. Nature Immunol. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
  • Zhang et al., 2020. Mol Therapy. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
  • Stromnes et al., 2019. Can Imm Res. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma
  • Yu et al., 2020. Nature Comm. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint
  • Arina et al., 2019. Nature Comm. Tumor-reprogrammed resident T cells resist radiation to control tumors
  • Wang et al., 2020. Nature Comm. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
  • Mayoux et al., 2020. Sci Transl Med. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
  • Jaynes et al., 2020 Sci Transl Med Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses
  • Strauss et al., 2020 Sci Immunol Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
  • Yamamoto et al., 2020 Nature Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
  • Leone et al., 2019 Science Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
  • Urban et al., 2020 Nature Immunol Peripherally induced brain tissue–resident memory CD8+ T cells mediate protection against CNS infection
  • Shi et al., 2019 Mol Therapy Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy
  • Spindler et al., 2020 Nature Biotech Massively parallel interrogation and mining of natively paired human TCRαβ repertoires
  • Evgin et al., 2020 Nature Comm Oncolytic virus-derived type I interferon restricts CAR T cell therapy
  • Hsu et al., 2020 Nature Comm Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties
  • Huff et al., 2020 Mol Therapy Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses
  • Salzer et al., 2020 Nature Comm Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function
  • Acharaya et al., 2020 Immunity Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment
  • Yamazaki et al., 2020 Nature Immunol Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
  • Park et al., 2020 Sci Transl Med Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
  • Diskin et al., 2020 Nature Immunol PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
  • Lakins et al., 2020 Clin Cancer Res FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models
  • Baharom et al., 2020 Nature Immunol Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
  • Such et al., 2020 JCI Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy
  • Klemm et al., 2020 Cell Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
  • Cichocki et al., 2020 Sci Transl Med iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
  • Au et al., 2020 Sci Adv Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
  • Polack et al., 2020 NEJM Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
  • Yu et al., 2020 Nature Med Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
  • Cai et al., 2020 Mol Oncol Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1
  • You et al, 2020 J Immunother cancer Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
  • Wang et al., 2020 PlosOne Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function
  • Mosaheb et al., 2020 Nature Comm Genetically stable poliovirus vectors activate dendritic cells and prime anti-tumor CD8 T cell immunity
  • Krishna et al., 2020 Science Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
  • Samstein et al., 2020 Nature Cancer Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
  • Xu et al., 2020 JEM STING agonist promotes CAR T cell trafficking and persistence in breast cancer
  • Wu et al., 2020 Nature Peripheral T cell expansion predicts tumour infiltration and clinical response
  • Yang et al., 2021 Nature Comm Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
  • Solomon et al., 2020 Nature Cancer CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
  • Liu et al., 2020 Cell Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
  • Fu et al., 2021 Can Imm Res DGKA Mediates Resistance to PD-1 Blockade
  • Platten et al., 2021 Nature A vaccine targeting mutant IDH1 in newly diagnosed glioma
  • Shield V et al., 2021 Science Advances Cellular backpacks for macrophage immunotherapy
  • Kaczanowska et al., 2021 Cell Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis

to top
powered by webEdition CMS